Your browser doesn't support javascript.
loading
The First Case of HER2+ Invasive Ductal Carcinoma Arising From a Breast Hamartoma and Literature Review.
Baer, Lea; Rogers, Sherise Chantell; Farrelly, Patricia; Tornos, Carmen; Sweeney, Keith.
Afiliación
  • Baer L; Department of Hematology and Oncology, Stony Brook University Hospital, NY, USA. Electronic address: lea.baer@stonybrookmedicine.edu.
  • Rogers SC; Department of Internal Medicine, Stony Brook University Hospital, NY, USA.
  • Farrelly P; Division of Breast and Oncologic Surgery, Stony Brook University Hospital, NY, USA.
  • Tornos C; Department of Pathology, Stony Brook University Hospital, NY, USA.
  • Sweeney K; Department of Pathology, Stony Brook University Hospital, NY, USA.
J Natl Med Assoc ; 109(1): 55-59, 2017.
Article en En | MEDLINE | ID: mdl-28259217
ABSTRACT
Carcinomas arising from breast hamartomas are exceedingly rare. We present the first reported case of an African-American female presenting with a right breast lump and a subsequent mammogram suggestive of a hamartoma. She later underwent lumpectomy and was found to have HER2+ invasive ductal carcinoma (IDC) arising from a hamartoma. She was amenable to HER2-targeted trastuzumab, hormone therapy and adjuvant radiation but declined chemotherapy. In a review of the literature, IDC is the predominant neoplastic type found in hamartomas. The average hamartoma size at time of neoplasm diagnosis is 6.0 cm. Patients with hamartomas greater than 6.0 cm, with changes in calcification pattern; new nodules or asymmetry should be considered for additional evaluation with ultrasound, MRI and/or biopsy. HER2 status is under-reported among cases and should be evaluated in any malignancy found within hamartomas as HER-2 therapy has improved overall survival and recurrence free survival in HER2+breast cancer patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Mama / Neoplasias de la Mama / Carcinoma Ductal de Mama / Receptor ErbB-2 / Terapia Molecular Dirigida / Hamartoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: J Natl Med Assoc Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de la Mama / Neoplasias de la Mama / Carcinoma Ductal de Mama / Receptor ErbB-2 / Terapia Molecular Dirigida / Hamartoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: J Natl Med Assoc Año: 2017 Tipo del documento: Article
...